Tirzepatide Titration Schedule: Week-by-Week Tracking Guide

Tirzepatide (Mounjaro/Zepbound) uses a dose-escalation ladder that takes months to climb. Unlike semaglutide's relatively straightforward titration, tirzepatide has 5 dose levels, each lasting at least 4 weeks. Rush it and you'll be miserable. Go too slow and you delay results.

The problem: most users lose track of where they are in the schedule. They can't remember which week they started the current dose. They don't know if their side effects are “normal for week 2 of this dose” or a sign they escalated too fast.

This guide covers the standard titration framework, what to track at each level, and how to know when you're actually ready to increase.

The Standard Tirzepatide Titration Ladder

The FDA-approved dose escalation for tirzepatide follows a minimum 4-week hold at each level before increasing:

Key point: The 2.5mg starting dose is not a therapeutic dose. It exists solely to let your GI system adapt. If you're “not feeling anything” at 2.5mg, that's expected. Don't skip ahead.

Why Tracking Matters More Than the Schedule

The schedule above is a framework, not a prescription. Some users stay at 5mg for 8 weeks because it's working. Others need to slow down because side effects are severe at 7.5mg.

The decisions you'll make during titration:

• “Am I ready to increase?” — Requires knowing how you responded over the last 4 weeks, not just the last 3 days
• “Should I hold at this dose longer?” — If side effects are still significant in week 4, extending makes sense
• “Should I step back down?” — Some users find their optimal dose is lower than maximum
• “Is this side effect new or recurring?” — Pattern detection requires data, not memory

Without tracking, you're making these decisions from feeling. With tracking, you're making them from data.

Week-by-Week: What to Expect and Track

Phase 1: 2.5mg (Weeks 1-4)

What to expect:

• Mild appetite suppression (or none at all)
• Possible mild nausea, especially days 1-3 after injection
• Minimal weight change
• Some users feel nothing — this is normal and expected

What to track:

• Injection date and time (establish your weekly day)
• Injection site (start your rotation pattern now)
• GI symptoms (nausea, bloating, constipation) — severity 1-5
• Weekly weight (same day, same conditions)
• Appetite changes (noticed/not noticed)

Ready to increase when: Minimal GI side effects by week 3-4. Doesn't matter if you haven't lost weight — 2.5mg is about tolerance, not results.

Phase 2: 5mg (Weeks 5-8)

What to expect:

• Noticeable appetite reduction — this is the first therapeutic dose
• GI side effects may return for 1-2 weeks then settle
• Initial weight loss begins (typically 1-3 lbs/week)
• Food noise reduction — fewer cravings and intrusive food thoughts

What to track:

• Everything from Phase 1, plus:
• Weekly weight trend (not daily — fluctuations cause anxiety)
• Energy levels (some users report fatigue during adaptation)
• Food intake changes (qualitative — are you eating less? different foods?)

Ready to increase when: Side effects manageable by week 3-4 AND weight loss has plateaued or you're responding well and your provider recommends it. Many users stay at 5mg for 8+ weeks if it's working.

Consider staying if: Consistent 1-2 lbs/week loss with tolerable side effects. You don't need the maximum dose — you need the effective dose.

Phase 3: 7.5mg (Weeks 9-12)

What to expect:

• Stronger appetite suppression
• GI side effects may intensify (nausea is most common)
• Some users report this is the “hardest” transition
• Weight loss typically accelerates

What to track:

• All previous metrics, plus:
• Meal timing relative to injection day (nausea often worse within 48 hours of injection)
• Hydration — constipation becomes more common at higher doses
• Any new symptoms (hair changes, heartburn, sulfur burps)

Ready to increase when: Adapted with manageable symptoms AND need additional efficacy. This is where many users find their “cruise dose” — the level that works without being miserable.

Phase 4: 10mg (Weeks 13-16)

What to expect:

• Strong appetite suppression — some users struggle to eat enough
• Significant weight loss if it hasn't plateaued
• Side effects usually stabilize after 2 weeks if you've titrated properly

What to track:

• Protein intake — muscle preservation matters at aggressive weight loss rates
• Energy and exercise capacity
• Non-scale metrics: measurements, how clothes fit, functional improvements

Phase 5: 12.5-15mg (Weeks 17+)

Maximum dose. Not everyone needs to reach this level. If you're losing weight steadily at 7.5mg or 10mg, there's no reason to increase.

Track the same metrics, but also note whether the increased dose provides meaningful additional benefit compared to the previous level. If the side effects increased but the results didn't, your previous dose may have been the sweet spot.

Compounded Tirzepatide: The Extra Math

If you're using compounded tirzepatide (multi-dose vial instead of branded pen), you have an additional tracking layer: draw volume calculation.

Compounded tirzepatide comes in varying concentrations. Common ones:

• 5mg/ml — for lower doses (2.5mg = 0.5ml)
• 10mg/ml — for mid-range doses (5mg = 0.5ml)
• 20mg/ml — for higher doses (10mg = 0.5ml)

As you titrate up, you may need to switch concentrations. A 5mg/ml vial at the 10mg dose level means drawing 2ml — that's a lot of liquid for a subQ injection.

Track which concentration you're using alongside your dose level. A “dose increase” might actually be a “same draw volume, higher concentration vial.” These are easy to confuse, and confusing them means a significant dosing error.

Side Effect Checkpoints: When to Hold vs. Increase

Use this framework at the end of each 4-week phase:

Increase if:

• GI side effects resolved or minimal (≤2/5 severity)
• Appetite suppression has noticeably decreased from earlier in this phase
• Weight loss has slowed or plateaued at current dose
• Your provider recommends escalation

Hold at current dose if:

• Still losing weight at a good rate (1-2 lbs/week)
• Side effects are manageable but still present
• You're only in week 3-4 and still adapting

Step back down if:

• Severe nausea or vomiting lasting more than 3-4 days after each injection
• Unable to eat enough to meet basic nutritional needs
• Side effects significantly impacting quality of life after 2+ weeks at this dose

Having 4 weeks of logged data makes these decisions clear. Without logs, you're guessing whether “it was bad this week” means “bad for this dose in general” or “bad because I ate pizza 30 minutes after injecting.”

Tirzepatide vs Semaglutide Titration: Key Differences

If you've titrated semaglutide before, tirzepatide has some differences:

• Dual mechanism: Tirzepatide targets both GIP and GLP-1 receptors. Semaglutide targets GLP-1 only. This generally means stronger appetite suppression but also potentially more GI side effects.
• Larger dose jumps: Going from 5mg to 7.5mg is a 50% increase. Semaglutide's jumps are proportionally larger too, but tirzepatide's absolute mg increases are bigger.
• More titration steps: 5 dose levels vs semaglutide's 4-5. The full titration takes longer.

The Minimum Viable Tracking System

At minimum, log these weekly:

1. Injection date, time, and site
2. Current dose level and week number at this dose
3. GI symptom severity (1-5) for days 1-3 post-injection
4. Weekly weight (same day, same conditions — morning, post-bathroom, pre-food)
5. Appetite rating (1-5: 1 = no appetite, 5 = normal hunger)
6. Notes — anything unusual (food reactions, stress, illness, travel)

This takes 60 seconds per week. Over 16-20 weeks of titration, it creates a complete record that makes dose decisions evidence-based instead of guess-based.

Related

• Semaglutide titration schedule (week by week)
• Injection site rotation: why it matters
• How to calculate peptide dose after reconstitution
• What to track during a peptide cycle

Disclaimer: This is educational information about tirzepatide titration frameworks, not medical advice. Dose changes should be made in consultation with your prescribing healthcare provider. Titer is a tracking tool — it does not prescribe or recommend specific doses.